Detalles de la búsqueda
1.
Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
Breast Cancer Res Treat
; 139(2): 553-60, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23686417
2.
Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998.
Onkologie
; 36(12): 727-36, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24356564
3.
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 134(3): 1149-59, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22763464
4.
Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.
Biochem Biophys Res Commun
; 414(1): 226-32, 2011 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-21945930
5.
Primary tumor excision in stage IV breast cancer at diagnosis without influence on survival: a retrospective analysis and review of the literature.
Onkologie
; 34(11): 607-12, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22104157
6.
5FU continuous infusion in heavily pretreated advanced breast cancer patients.
Onkologie
; 34(12): 696-700, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22156449
7.
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Onkologie
; 33(4): 155-66, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20389141
8.
Therapeutic implication of BAL in patients with neutropenia.
Ann Hematol
; 88(12): 1249-56, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19415277
9.
ACT-FASTER, a Prospective Cohort Study Exploring Treatment Patterns with Fulvestrant and Exemestane in Postmenopausal Patients with Advanced Hormone Receptor-Positive Breast Cancer under Real-Life Conditions in Germany.
Breast Care (Basel)
; 14(6): 401-408, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31933587
10.
Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Eur J Pharmacol
; 591(1-3): 43-51, 2008 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-18588872
11.
Prescription pattern of aromatase inhibitors for the adjuvant therapy of breast cancer in Germany - results of the second survey among gynaecologists and medical oncologists.
Onkologie
; 31(1-2): 19-25, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18268395
12.
Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.
Anticancer Res
; 38(5): 2669-2682, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29715087
13.
The effect of induced hyperthermia on the immune system.
Prog Brain Res
; 162: 137-52, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17645918
14.
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
J Clin Oncol
; 23(3): 432-40, 2005 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-15659490
15.
Pretreatment of BMSCs with TZD solution decreases the proliferation rate of MCF7 cells by reducing FGF4 protein expression.
Mol Med Rep
; 13(4): 3406-14, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26934829
16.
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.
J Clin Oncol
; 21(11): 2147-55, 2003 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12775740
17.
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
J Clin Oncol
; 20(12): 2805-11, 2002 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12065557
18.
Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
J Cancer Res Clin Oncol
; 131(9): 568-74, 2005 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16044345
19.
Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography.
Clin Cancer Res
; 9(8): 3047-51, 2003 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12912955
20.
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Clin Cancer Res
; 9(4): 1436-40, 2003 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-12684416